Expanding the Use of Immunoscore in Early-Stage CRC

Jerome Galon, PhD
Published: Thursday, Jun 20, 2019



Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses ways to expand the use of Immunoscore in early-stage colorectal cancer (CRC).

At the 2019 ASCO Annual Meeting, the IDEA study evaluated the benefit of 3 months of adjuvant chemotherapy versus 6 months in patients with stage III CRC. Researchers demonstrated that patients with an intermediate or high Immunoscore seemed to respond better to 6 months of FOLFOX. In contrast, patients with a low Immunoscore did not derive any additional benefit from 6 months of treatment versus 3 months of treatment.

Galon says the clinical utility of Immunoscore should be validated for other chemotherapy regimens like CAPOX, which is also used in the stage III setting. A similar study to IDEA should be conducted. Furthermore, in the stage II space, Immunoscore has been shown to effectively distinguish between high- and low-risk patients. As such, Immunoscore could have a role in determining which patients need chemotherapy or not in that setting as well.
SELECTED
LANGUAGE


Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses ways to expand the use of Immunoscore in early-stage colorectal cancer (CRC).

At the 2019 ASCO Annual Meeting, the IDEA study evaluated the benefit of 3 months of adjuvant chemotherapy versus 6 months in patients with stage III CRC. Researchers demonstrated that patients with an intermediate or high Immunoscore seemed to respond better to 6 months of FOLFOX. In contrast, patients with a low Immunoscore did not derive any additional benefit from 6 months of treatment versus 3 months of treatment.

Galon says the clinical utility of Immunoscore should be validated for other chemotherapy regimens like CAPOX, which is also used in the stage III setting. A similar study to IDEA should be conducted. Furthermore, in the stage II space, Immunoscore has been shown to effectively distinguish between high- and low-risk patients. As such, Immunoscore could have a role in determining which patients need chemotherapy or not in that setting as well.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x